Sue-Jean Lin sold $778k of ARQT
director at Arcutis Biotherapeutics, Inc.. 25,272 shares at an average of $30.78, traded Nov 24, 2025, filed Nov 25, 2025.
Score components
- +15RoleDirector
- +22Trade size$778k at market
- +10Share of holdings soldSold 49% of holdings
- +15Cluster6 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001867788-25-000005, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 24, 2025 | MOption exercise Common Stock | +18,052 | $8.63 | $156k | 44,787 | Nov 25, 2025 |
| Nov 24, 2025 | MOption exercise Common Stock | +7,220 | $7.51 | $54k | 52,007 | Nov 25, 2025 |
| Nov 24, 2025 | SOpen-market sale Common Stock | -25,272 | $30.78 | $778k | 26,735 | Nov 25, 2025 |
| Nov 24, 2025 | MOption exercise Stock Option (right to buy)derivative | -18,052 | $0.00 | $0 | 9,000 | Nov 25, 2025 |
| Nov 24, 2025 | MOption exercise Stock Option (right to buy)derivative | -7,220 | $0.00 | $0 | 5,000 | Nov 25, 2025 |
Related signals
Other insiders at Arcutis Biotherapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 12Weak | Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $92k 3,674 shares | -3% | |
| 3Weak | Arcutis Biotherapeutics, Inc. | Howard G. Welgus director | $114k 4,730 shares | -12% | |
| 16Weak | Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $250k 9,989 shares | -8% | |
| 15Weak | Arcutis Biotherapeutics, Inc. | Patrick Burnett See Remarks | $333k 11,500 shares | -10% | |
| 17Weak | Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $50k 1,657 shares | -1% | |
| 29Weak | Arcutis Biotherapeutics, Inc. | Howard G. Welgus director | $302k 10,000 shares | -11% | |
| 35Weak | Arcutis Biotherapeutics, Inc. | Todd Watanabe See Remarks | $1.5M 50,000 shares | -6% | |
| 42Moderate | Arcutis Biotherapeutics, Inc. | Halley E Gilbert director | $455k 16,532 shares | -43% | |
| 18Weak | Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $72k 2,550 shares | -2% | |
| 39Weak | Arcutis Biotherapeutics, Inc. | Neha Krishnamohan director | $939k 40,504 shares | -65% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.